Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas

(2020) Salvatore Lopez et al.   Oncotarget

Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy

(2020) David M. Goldenberg et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).

(2020) Aaron Elliott Lisberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

(2020) K. Kalinsky et al.   ANNALS OF ONCOLOGY

Antibody–Drug Conjugates: The Last Decade

(2020) Nicolas Joubert et al.   Pharmaceuticals

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

(2019) Aditya Bardia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody-Drug Conjugate-Based Therapeutics: State of the Science

(2019) Michael J Birrer et al.   JNCI-Journal of the National Cancer Institute

Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.

(2019) Scott T. Tagawa et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index

(2019) Steven Coats et al.   CLINICAL CANCER RESEARCH

Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan

(2019) David M. Goldenberg et al.   mAbs

In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma

(2019) Chanhee Han et al.   GYNECOLOGIC ONCOLOGY

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

(2019) Emanuele Perrone et al.   Molecular Oncology

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

(2018) David M. Goldenberg et al.   Oncotarget

Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice

(2018) Tanios Bekaii-Saab et al.   Clinical Colorectal Cancer

Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

(2017) Rebecca Suk Heist et al.   JOURNAL OF CLINICAL ONCOLOGY

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

(2015) Thomas M. Cardillo et al.   BIOCONJUGATE CHEMISTRY

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

(2015) A. N. Starodub et al.   CLINICAL CANCER RESEARCH

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

(2015) David M. Goldenberg et al.   Oncotarget

Milatuzumab-SN-38 Conjugates for the Treatment of CD74+ Cancers

(2013) S. V. Govindan et al.   MOLECULAR CANCER THERAPEUTICS

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

(2012) F. Andre et al.   ANNALS OF ONCOLOGY

Upregulation of Trop-2 quantitatively stimulates human cancer growth

(2012) M Trerotola et al.   ONCOGENE

Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

(2011) T. M. Cardillo et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

(2011) Carol Aghajanian et al.   JOURNAL OF CLINICAL ONCOLOGY